The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice

Zhang,Leiming; Song,Yanqin; Lu,Chengwen; Zhang,Jianqiao; Yuan,Jiani; Wang,Tian; Fu,Fenghua

doi:10.3892/etm.2013.883

March 2013 Volume 5 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March 2013 Volume 5 Issue 3

Full Size Image

Article

The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice

Authors:
- Leiming Zhang
- Yanqin Song
- Chengwen Lu
- Jianqiao Zhang
- Jiani Yuan
- Tian Wang
- Fenghua Fu
View Affiliations / Copyright

Affiliations: Department of Pharmacology, School of Pharmacy, Yantai University, Yantai, Shandong 264005, P.R. China
Pages: 793-796
|
Published online on: January 4, 2013

https://doi.org/10.3892/etm.2013.883
Expand metrics +

Abstract

The acetylcholinesterase inhibitor (AChEI), huperzine A has been used in the treatment of the cognitive deterioration associated with Alzheimer's disease (AD). However, the side-effects of huperzine A associated with increased cholinergic activity, particularly in the gastrointestinal system, are evident. It is not yet known how quickly these side-effects become tolerated; this information would provide guidance to doctors on how to use huperzine A so as to attenuate the adverse events. The present study aimed to observe the effects of huperzine A on gastrointestinal motility and acetylcholinesterase (AChE) activity in mice. After oral administration of huperzine A with single and multiple dosing, the gastrointestinal motility and AChE activity of the mice were examined. The results revealed that, following a single dose of huperzine A, the AChE activity in the stomach and duodenum were significantly inhibited and the gastrointestinal motility was significantly increased. However, following multiple doses (7 or 28 doses, one dose per day), no significant changes in the AChE activity and gastrointestinal motility were identified. These findings indicate that the gastrointestinal adverse effects of huperzine A may be well-tolerated relatively quickly and do not recur. Additionally, it suggests that patients with AD are likely to have minimal gastrointestinal side-effects after taking multiple doses of huperzine A.

View Figures

View References

1.	Francis PT, Palmer AM, Snape M and Wilcock GK: The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 66:137–147. 1999.
2.	Pohanka M: Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 155:219–229. 2011. View Article : Google Scholar : PubMed/NCBI
3.	Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 25:CD0055932006.
4.	Mimica N and Presecki P: Side effects of approved antidementives. Psychiatr Danub. 21:108–113. 2009.
5.	Farlow M, Veloso F, Moline M, et al: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol. 11:572011.
6.	Alva G and Cummings JL: Relative tolerability of Alzheimer’s disease treatments. Psychiatry (Edgmont). 5:27–36. 2008.
7.	Wang R, Yan H and Tang XC: Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 27:1–26. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Ellman GL, Courtney KD, Andres V Jr and Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7:88–95. 1961. View Article : Google Scholar : PubMed/NCBI
9.	Rogers RC, McTigue DM and Hermann GE: Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev. 20:57–66. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Shiba Y, Mizumoto A, Inatomi N, Haga N, Yamamoto O and Itoh Z: Stimulatory mechanism of EM523-induced contractions in postprandial stomach of conscious dogs. Gastroenterology. 109:1513–1521. 1995. View Article : Google Scholar : PubMed/NCBI
11.	Furuichi A, Makimoto N, Ogishima M, et al: In vivo assessment of the regulatory mechanism of cholinergic neuronal activity associated with motility in dog small intestine. Jpn J Pharmacol. 86:73–78. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Iwanaga Y, Miyashita N, Morikawa K, Mizumoto A, Kondo Y and Itoh Z: A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology. 99:401–408. 1990.
13.	Ueki S, Seiki M, Yoneta T, et al: Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 264:152–157. 1993.PubMed/NCBI
14.	Wang Y, Tang XC and Zhang HY: Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. J Neurosci Res. 90:508–517. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Zhu XD and Tang XC: Improvement of impaired memory in mice by huperzine A and huperzine B. Zhongguo Yao Li Xue Bao. 9:492–497. 1988.(In Chinese).

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The effects of huperzine A on gastrointestinal acetylcholinesterase activity and motility after single and multiple dosing in mice

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles